Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 2/20 | 0.55 |
| ▸ | CA2 | P00918 | 2/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA7 | P43166 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.54 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | ACHE | P22303 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 2/20 | 0.48 |
| ▸ | MAOB | P27338 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL120603 | 1.00 | CYP1A2 (0.55) | CYP1A2CYP2D6CYP2C19CA1CA2 | |
| SCHEMBL57137 | 1.00 | CYP1A2 (0.55) | CYP1A2CYP2D6CYP2C19CA1CA2 | |
| Hydrochloric Acid SCHEMBL28704563 | 0.98 | CYP1A2 (0.53) | CYP1A2CYP2D6CYP2C19CA1CA2 | |
| Bromide SCHEMBL28602504 | 0.98 | CYP1A2 (0.53) | CYP1A2CYP2D6CYP2C19CA1CA2 | |
| Hydrochloric Acid SCHEMBL2186508 | 0.98 | CYP1A2 (0.53) | CYP1A2CYP2D6CYP2C19CA1CA2 | |
| Hydrochloric Acid SCHEMBL28706049 | 0.98 | CYP1A2 (0.53) | CYP1A2CYP2D6CYP2C19CA1CA2 | |
| SCHEMBL756642 | 0.93 | LTA4H (0.52) | CYP1A2CYP2D6CYP2C19CA1CA2 | |
| SCHEMBL30913870 | 0.93 | ALOX5 (0.53) | CYP1A2CYP2D6CYP2C19CA1CA2 | |
| Propane SCHEMBL29187532 | 0.93 | CYP1A2 (0.55) | CYP1A2CYP2D6CYP2C19CA1CA2 | |
| Acetic Acid SCHEMBL11035019 | 0.88 | ALOX5 (0.49) | CYP1A2CYP2D6CYP2C19CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 905 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250387385-A1 | TREATMENT FOR GLOMERULAR DISEASES | ZYDUS LIFESCIENCES LIMITED (IN) | 2025-12-25 | — | — | US | claimed |
| EP-4565233-A1 | TREATMENT FOR APLASTIC ANEMIA (AA) | Zydus Lifesciences Limited (IN) | 2025-06-11 | — | — | EP | claimed |
| EP-4539934-A1 | TREATMENT FOR GLOMERULAR DISEASES | Zydus Lifesciences Limited (IN) | 2025-04-23 | — | — | EP | claimed |
| US-20250078176-A1 | ENVIRONMENTAL ATTRIBUTES FOR NITROGEN CONTAINING CHEMICALS | BASF SE (DE) | 2025-03-06 | — | — | US | claimed |
| CN-119119035-A | RIPK1 kinase target inhibitor and preparation method and application thereof | 中山大学 | 2024-12-13 | — | — | CN | claimed |
| WO-2024216075-A1 | SYNTHESIS OF MAVORIXAFOR AND INTERMEDIATES THEREOF | X4 PHARMACEUTICALS, INC. (US) | 2024-10-17 | — | — | WO | claimed |
| CN-118435582-A | Environmental attributes of nitrogen-containing chemicals | 巴斯夫欧洲公司 | 2024-08-02 | — | — | CN | claimed |
| CN-118307400-A | Preparation method of S-flurbiprofen | 金仓(上海)医药生物科技有限公司 | 2024-07-09 | — | — | CN | claimed |
| CN-118185900-A | Transaminase, preparation method and application thereof, and preparation method of amino-containing compound | 爱斯特（成都）生物制药股份有限公司 | 2024-06-14 | — | — | CN | claimed |
| US-20240173314-A1 | TREATMENT OF SICKLE CELL ANAEMIA | ZYDUS LIFESCIENCES LTD. (IN) | 2024-05-30 | — | — | US | claimed |
| US-20080076814-A1 | Hexahydro-Cyclooctyl Pyrazole Cannabinoid Modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-27 | — | — | US | claimed |
| US-20070238880-A1 | Diastereoselective Synthesis Process for the Preparation of Imidazole Compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-11 | — | — | US | claimed |
| US-7135570-B2 | Synthesis of enantiomerically pure amino-substituted fused bicyclic rings | ANORMED INC. (CA) | 2006-11-14 | — | — | US | claimed |
| US-20060229315-A1 | 3-Substituted Quinoline-4-Carboxamide Derivatives as NK-3 and NK-2 Receptor Antagonists | GLAXOSMITHKLINE S.P.A. (IT) | 2006-10-12 | — | — | US | claimed |
| EP-1659120-A1 | 3-substituted quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists | GlaxoSmithKline S.p.A. (IT) | 2006-05-24 | — | — | EP | claimed |
| US-20050080267-A1 | Synthesis of enantiomerically pure amino-substituted fused bicyclic rings | ANORMED, INC. (CA) | 2005-04-14 | — | — | US | claimed |
| US-20040180902-A1 | 3-Substituted quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists | SMITHKLINE BEECHAM S.P.A. (IT) | 2004-09-16 | — | — | US | claimed |
| US-6677337-B2 | RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, INFLAMMATORY BOWEL DISEASE, CACHEXIA, SEPTIC SHOCK, CARDIOVASCULAR AND RESPIRATORY SYSTEM DISORDERS | THE PROCTER & GAMBLE COMPANY | 2004-01-13 | — | — | US | claimed |
| US-20030225082-A1 | 1,2-dihydropyrazol-3-ones which controls inflammatory cytokines | PROCTER & GAMBLE COMPANY, THE | 2003-12-04 | — | — | US | claimed |
| US-20030114679-A1 | Synthesis of enantiomerically pure amino-substituted fused bicyclic rings | ANORMED CORPORATION (CA) | 2003-06-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180902-A1 | 3-Substituted quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists | HRH4, HRH2, HRH3 | CYP1A2 1824/4885CYP2D6 1869/4885CYP2C19 2565/4885 |
| US-20030114679-A1 | Synthesis of enantiomerically pure amino-substituted fused bicyclic rings | CBR1, POR, CBR3 | CYP1A2 37/4885CYP2D6 123/4885CYP2C19 180/4885 |
| US-20050080267-A1 | Synthesis of enantiomerically pure amino-substituted fused bicyclic rings | CBR1, POR, CBR3 | CYP1A2 37/4885CYP2D6 123/4885CYP2C19 180/4885 |
| US-20070238880-A1 | Diastereoselective Synthesis Process for the Preparation of Imidazole Compounds | DHPS, CYP2S1, CYP1A2 | CYP1A2 3/4885CYP2D6 21/4885CYP2C19 28/4885 |
| US-20080076814-A1 | Hexahydro-Cyclooctyl Pyrazole Cannabinoid Modulators | CNR1, CNR2, FAAH | CYP1A2 726/4885CYP2D6 672/4885CYP2C19 429/4885 |
| US-20250387385-A1 | TREATMENT FOR GLOMERULAR DISEASES | SSB, GRN, ALB | CYP1A2 4800/4885CYP2D6 4820/4885CYP2C19 4404/4885 |
| US-20030225082-A1 | 1,2-dihydropyrazol-3-ones which controls inflammatory cytokines | IL1B, IL1A, IL1R1 | CYP1A2 545/4885CYP2D6 513/4885CYP2C19 836/4885 |
| US-20240173314-A1 | TREATMENT OF SICKLE CELL ANAEMIA | HBG1, HBB, HBG2 | CYP1A2 794/4885CYP2D6 843/4885CYP2C19 807/4885 |
| US-20060229315-A1 | 3-Substituted Quinoline-4-Carboxamide Derivatives as NK-3 and NK-2 Receptor Antagonists | KCNK3, KCNJ2, KCNK2 | CYP1A2 1434/4885CYP2D6 1124/4885CYP2C19 1439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.